Status:

COMPLETED

BCAA Supplementation for Concussion

Lead Sponsor:

Children's Hospital of Philadelphia

Collaborating Sponsors:

The Dana Foundation

Main Line Health

Conditions:

Brain Concussion

Eligibility:

All Genders

11-34 years

Phase:

PHASE2

Brief Summary

This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAA's) in the treatment of concussion. The aim of the study is to...

Detailed Description

Annually, between 100,000 to 140,000 children present to the emergency department for concussion in the United States.1 The Centers for Disease Control now estimates that 1.6 - 3.8 million sports rela...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Males and females, ages 11 - 34 years, of any race.
  • Subjects who had a concussion, as diagnosed by a qualified physician, within 72 hours prior to enrollment.
  • Ability to have daily email and internet access.
  • Females must have a negative urine pregnancy test and must use an acceptable method of contraception.
  • Subjects must, in the opinion of the referring physician, have the capacity to provide informed consent.
  • Informed consent by the subject, or for subjects \<18 years old both informed consent by a parent/guardian and child assent.
  • Exclusion Criteria
  • Witnessed seizure at the time of injury or penetrating head injury.
  • Prior concussion or TBI within 90 days.
  • Concussion or TBI severe enough to require admission to an intensive care unit for observation or intervention.
  • Previous history of TBI or concussion requiring admission to the hospital, disabling stroke, epilepsy, brain tumor, neurodegenerative condition, or psychiatric disease.
  • Subjects taking neurological or psychoactive medications as a regular daily prescription medication.
  • Known history of maple syrup urine disease or known family history of maple syrup urine disease.
  • Any investigational drug use within 30 days prior to enrollment.
  • Allergy to Food, Drug, and Cosmetic (FD\&C) Red #40 (red dye 40) or Sucralose.
  • Lactating females.
  • Parents/guardians or subjects who, in the opinion of the investigators, may be non-compliant with study schedules or procedures.

Exclusion

    Key Trial Info

    Start Date :

    January 1 2014

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 1 2023

    Estimated Enrollment :

    42 Patients enrolled

    Trial Details

    Trial ID

    NCT01860404

    Start Date

    January 1 2014

    End Date

    January 1 2023

    Last Update

    May 14 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, United States, 19104